Immatics Receives USD 58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies
Tuebingen, Germany and Houston, Texas, USA, October 04, 2017 / B3C newswire / -- Immatics, a leading company in the field of cancer immunotherapy, today announced the completion of its Series E financing, raising $58 million. The Series E funding was …